Antibacterial, Instant Clot-Forming Dressings via TXA–NO–Pro
2026-07-02
Integrating Tranexamic Acid and NO-Releasing Bi-Layers for Advanced Trauma Wound Dressings
Study Background and Research Question
Traumatic injuries, including those from accidents, gunshots, and shrapnel wounds, are a leading cause of morbidity and mortality worldwide, with uncontrolled hemorrhage and wound infection being the two most critical challenges. Immediate interventions that can both rapidly arrest bleeding and prevent microbial contamination are urgently needed, as excessive blood loss accounts for up to 30% of trauma-related deaths and infection is the second most common cause of mortality within 72 hours post-injury (Internal Article). The natural wound healing process leverages both hemostatic and immune mechanisms, but these can be easily overwhelmed in severe trauma. Nitric oxide (NO) has been identified as a key mediator in all phases of wound healing, offering both antibacterial and tissue-regenerative benefits. Tranexamic acid (TXA), an established antifibrinolytic agent, has been widely used systemically and topically to minimize blood loss by inhibiting fibrinolysis. Yet, the integration of these agents into a single wound dressing to simultaneously address hemostasis and infection risk has not been fully realized.Key Innovation from the Reference Study
The reference study develops a novel, bi-layer wound dressing that strategically combines three functional components: tranexamic acid (TXA), the NO donor S-nitroso-N-acetylpenicillamine (SNAP), and propolis, a natural resin with bioadhesive and antibacterial properties (internal review). The upper layer, in direct contact with the wound, utilizes a resinous bed of propolis infused with uniform concentrations of TXA. The underlying base layer contains SNAP embedded in a Carbosil® polymeric matrix. This configuration is designed to deliver immediate antifibrinolytic action at the wound interface (stabilizing the fibrin clot and preventing excessive blood loss) while providing a sustained release of NO for broad-spectrum antibacterial activity. What distinguishes this approach is the synergy between the rapid clot-stabilizing effect of TXA and the infection-preventing capabilities of NO and propolis. By preventing the lysis of fibrin—the primary mechanism of the inhibition of fibrinolysis—TXA ensures a stable clot forms quickly, while NO and propolis significantly reduce bacterial contamination. This addresses two of the most crucial clinical priorities in trauma care within a single dressing platform.Methods and Experimental Design Insights
To test the efficacy of the TXA–SNAP–propolis (T-SP) bi-layer dressing, the study employed a series of in vitro and ex vivo assays:- Bi-layer Fabrication: Propolis was integrated with TXA at 2.5%, 5%, and 7.5% (v/v) concentrations, forming the wound-contacting layer. The SNAP-containing Carbosil® base layer was constructed to provide consistent NO release.
- Platelet Adhesion and Clot Formation: The lactate dehydrogenase-based platelet adhesion assay measured early fibrin activation and clot density, with outcomes compared between T-SP formulations and controls.
- Ultrastructural Evaluation: Scanning electron microscopy (SEM) characterized the microarchitecture of the fibrin network formed on the dressing surface, confirming the presence and density of the clot.
- Antibacterial Testing: The antibacterial capabilities of the dressing were assessed against Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii, two clinically relevant pathogens in wound infections.
Protocol Parameters
- Propolis Concentration: 2.5%, 5%, or 7.5% (v/v) in the TXA–propolis layer for evaluating optimal clot formation and antibacterial synergy.
- Platelet Adhesion Assay: Assess fibrin activation at 15 minutes after dressing application for early hemostatic effect.
- SEM Imaging: Prepare dressings post-assay for ultrastructural analysis of fibrin network density and morphology.
- Antibacterial Assays: Quantify CFU reduction for S. aureus and A. baumannii following exposure to the bi-layer dressing; compare to non-NO-releasing and non-propolis controls.
Core Findings and Why They Matter
The study’s primary findings demonstrate that the 7.5% propolis T-SP dressing significantly enhances early fibrin activation and clot density within 15 minutes of application compared to controls. SEM imaging revealed a dense, stable fibrin network on the dressing surface, confirming effective inhibition of fibrinolysis by TXA. Notably, the antibacterial component achieved a 98.9 ± 1% reduction in S. aureus and a 99.4 ± 1% reduction in multidrug-resistant A. baumannii CFUs, indicating robust infection control (reference study). These outcomes are significant because they validate a dual-action strategy for wound management: rapid clot formation (critical for bleeding time reduction) and reliable antibacterial protection. The integration of antifibrinolytic and antimicrobial mechanisms within a single dressing addresses both immediate and secondary risks of trauma wounds, setting a new benchmark for emergency and military wound care applications.Comparison with Existing Internal Articles
Several recent reviews have explored the role of tranexamic acid in advanced wound care biomaterials and translational hemostasis strategies. The article "Tranexamic Acid: Mechanistic Leverage for Translational Hemostasis" provides a detailed analysis of TXA’s molecular mechanism as a competitive inhibitor of plasminogen activation, its experimental validation, and its practical application in next-generation trauma platforms. Similarly, "Tranexamic Acid: Antifibrinolytic Agent for Fibrinolysis Research" highlights the reproducibility of TXA-mediated clot stabilization in laboratory models, with particular emphasis on plasmin-induced neutrophil adherence assays and workflow optimization with high-purity TXA reagents. What distinguishes the current reference study is its demonstration of the synergistic effect between TXA, NO, and propolis in a physical wound dressing format. While previous works have validated the antifibrinolytic agent’s action in isolation or in systemic use, this bi-layer approach provides direct evidence for immediate hemostasis and infection control in a single, deployable device. The internal review "Instant Clot-Forming Wound Dressings with Tranexamic Acid and NO" outlines similar advances but with less focus on the propolis component’s synergy. The addition of a natural bioadhesive and the careful titration of propolis in the present study further enhance the translational potential and biocompatibility of the dressing.Limitations and Transferability
Despite the promising results, several limitations are noted:- In Vivo Validation: The dressing’s performance was characterized in vitro and ex vivo; comprehensive in vivo testing in animal trauma models and eventual clinical trials will be required to confirm efficacy and safety under real-world conditions.
- Wound Heterogeneity: The study does not address how the dressing performs across different wound types, sizes, or in the presence of heavy contamination or comorbidities.
- Material Stability and Storage: Long-term stability and shelf life of the NO donor and the bi-layer construct under field or austere conditions were not assessed.